Presentation is loading. Please wait.

Presentation is loading. Please wait.

Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)

Similar presentations


Presentation on theme: "Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)"— Presentation transcript:

1 Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Pharmacokinetically-Targeted (PK) Busulfan (Bu), Cyclophosphamide (TBC) Conditioning  Michael Scordo, MD, Valkal Bhatt, PharmD, Meier Hsu, MS, Antonio M. Omuro, MD, Matthew J. Matasar, MD MS, Lisa DeAngelis, MD, Parastoo Dahi, MD, Craig H. Moskowitz, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages S132-S133 (March 2016) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Analysis of Grade 3-5 Non-Hematologic Toxicities
Biology of Blood and Marrow Transplantation  , S132-S133DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Kaplan-Meier Curves for PFS and OS
Biology of Blood and Marrow Transplantation  , S132-S133DOI: ( /j.bbmt ) Copyright © Terms and Conditions


Download ppt "Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)"

Similar presentations


Ads by Google